Drug Trial Radar · NCT06353386
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
May 20, 2024
Primary completion
Jan 15, 2029
Study completion Jan 15, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Orion Corporation, Orion Pharma
- First posted
- Apr 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for the opevesostat-based treatment combinations. There will be no hypothesis testing in this study.
Conditions
- Prostatic Neoplasms, Castration-Resistant
Interventions
OpevesostatDrug
Oral Tablet
OlaparibDrug
Oral Tablet
DocetaxelDrug
IV Infusion
CabazitaxelDrug
IV Infusion
Fludrocortisone acetateDrug
Oral Tablet
DexamethasoneDrug
Oral Tablet
PrednisoneDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Up to approximately 28 days
- Number of participants who experience one or more adverse events (AEs)Time frame: Up to approximately 46 months
- Number of participants who discontinue study intervention due to an AETime frame: Up to approximately 46 months
- Prostate-specific antigen (PSA) response rateTime frame: Up to approximately 46 months
Locations
77 sites in 20 countries. Site status is shown where the registry gives one.
UCSD Moores Cancer Center ( Site 0039)
La Jolla, California
UCLA Hematology/Oncology - Santa Monica ( Site 0044)
Los Angeles, California
University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services ( Site 0051)
Miami, Florida
University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 0049)
Baltimore, Maryland
Rutgers Cancer Institute of New Jersey ( Site 0033)
New Brunswick, New Jersey
University Hospitals Cleveland Medical Center ( Site 0043)
Cleveland, Ohio
MEDICAL COLLEGE OF WISCONSIN-Cancer Center Clinical Trials Office ( Site 0020)
Milwaukee, Wisconsin
Macquarie University-MQ Health Clinical Trials Unit ( Site 0108)
Macquarie University, New South Wales, Australia
Gallipoli Medical Research Ltd-GMRF CTU ( Site 0107)
Greenslopes, Queensland, Australia
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0110)
Melbourne, Victoria, Australia
Centre Hospitalier de l'Université de Montréal ( Site 0200)
Montreal, Quebec, Canada
Jewish General Hospital ( Site 0206)
Montreal, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0207)
Québec, Quebec, Canada
CIDO SpA-Oncology ( Site 0302)
Temuco, Biobio, Chile
Clinica Universidad Catolica del Maule-Oncology ( Site 0304)
Talca, Maule Region, Chile
Fundación Arturo López Pérez ( Site 0301)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 0303)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0300)
Santiago, Region M. de Santiago, Chile
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0406)
Bogotá, Bogota D.C., Colombia
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 0402)
Bogotá, Bogota D.C., Colombia
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0400)
Valledupar, Cesar Department, Colombia
IMAT S.A.S ( Site 0404)
Montería, Departamento de Córdoba, Colombia
Fundación Valle del Lili-Oncology CIC ( Site 0403)
Cali, Valle del Cauca Department, Colombia
Herlev and Gentofte Hospital ( Site 0501)
Copenhagen, Capital Region, Denmark
Aalborg Universitetshospital, Syd ( Site 0503)
Aalborg, North Denmark, Denmark
Vaasan Keskussairaala ( Site 0603)
Vaasa, Pohjanmaa, Finland
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 0604)
Helsinki, Uusimaa, Finland
Docrates Syöpäsairaala ( Site 0602)
Helsinki, Uusimaa, Finland
Hôpital Européen Georges Pompidou-Service d'Oncologie Médicale ( Site 0702)
Paris, France
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0703)
Bordeaux, Aquitaine, France
Hopitaux Universitaires de Strasbourg ( Site 0700)
Strasbourg, Bas-Rhin, France
Gustave Roussy ( Site 0701)
Villejuif, Île-de-France Region, France
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0800)
Berlin, Germany
Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 0804)
Hamburg, Germany
Universitaetsklinikum Heidelberg ( Site 0805)
Heidelberg, Baden-Wurttemberg, Germany
Universitaetsklinikum Tuebingen-Urologie ( Site 0801)
Tübingen, Baden-Wurttemberg, Germany
klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 0802)
Munich, Bavaria, Germany
Cork University Hospital ( Site 0902)
Cork, Ireland
Tallaght University Hospital ( Site 0900)
Dublin, Ireland
St. Vincent's University Hospital ( Site 0901)
Dublin, Dublin, Ireland
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.